What's New with AHA/ACC Guidelines for the Management of Lipid Disorders?
29
This program presents the most current guideline updates and pharmacologic options for lipid management recommended by the American College of Cardiology/American Heart Association. With a focus on atherosclerotic cardiovascular disease risk reduction, medical history, lipid panel, and CAC scoring are analyzed. Building upon the HMG-CoA reductase inhibitors, additional therapeutic agents for the high-risk patient are considered, with the latest evidence-based analysis of indication, risk, and safety. Cholesterol absorption inhibitors, PCSK9 inhibitors, and ACL inhibitors are all explored as they apply to current guideline-driven management.